A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes
Aims. Prediabetes has been proved as an important risk factor of both diabetes and cardiovascular disease (CVD). Previous studies have shown that both lifestyle intervention and pioglitazone may delay the development of diabetes in patients with prediabetes. However, no study has ever explored wheth...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2022/2971382 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553277857726464 |
|---|---|
| author | Yingying Luo Hongyuan Wang Xianghai Zhou Cuiqing Chang Wei Chen Xiaohui Guo Jinkui Yang Linong Ji Sanjoy K. Paul |
| author_facet | Yingying Luo Hongyuan Wang Xianghai Zhou Cuiqing Chang Wei Chen Xiaohui Guo Jinkui Yang Linong Ji Sanjoy K. Paul |
| author_sort | Yingying Luo |
| collection | DOAJ |
| description | Aims. Prediabetes has been proved as an important risk factor of both diabetes and cardiovascular disease (CVD). Previous studies have shown that both lifestyle intervention and pioglitazone may delay the development of diabetes in patients with prediabetes. However, no study has ever explored whether these interventions could revert prediabetes to normal glycemic status as the primary outcome. Interventions that may revert prediabetes back to normal glucose status would be of great clinical importance. Materials and Methods. We conducted a randomized, multicenter, 2×2 factorial designed study to examine whether intensive lifestyle intervention and/or pioglitazone could revert prediabetes to normal glucose tolerance. The participants were followed up for three years unless they reverted to normal glucose state or developed diabetes at the annual oral glucose tolerance test (OGTT). Reversion to normal glucose tolerance was confirmed on the basis of the results of OGTT. Results. In our study, 1945 eligible patients were ultimately randomized into four groups. In this three-year follow-up study, overall, 60.0%, 50.3%, 56.6% and 65.1% reverted back to normoglycemic state over 3 years of follow-up in the conventional lifestyle intervention plus placebo, intensive lifestyle intervention plus placebo, conventional lifestyle intervention plus pioglitazone, and intensive lifestyle intervention plus pioglitazone groups, respectively. Compared to the conventional lifestyle intervention plus placebo group, all the other three groups did not show any significant benefit in terms of reverting back to normoglycemic state. Conclusion. In our study, for patients with prediabetes, neither intensive lifestyle intervention nor pioglitazone had led to a higher reversion rate to normal glucose state. Trail registration.http://www.chictr.org.cn: ChiCTR-PRC-06000005. |
| format | Article |
| id | doaj-art-9341df1ed68143688548e07b942d524e |
| institution | Kabale University |
| issn | 2314-6753 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-9341df1ed68143688548e07b942d524e2025-02-03T05:54:30ZengWileyJournal of Diabetes Research2314-67532022-01-01202210.1155/2022/2971382A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with PrediabetesYingying Luo0Hongyuan Wang1Xianghai Zhou2Cuiqing Chang3Wei Chen4Xiaohui Guo5Jinkui Yang6Linong Ji7Sanjoy K. Paul8Department of Endocrinology and MetabolismDepartment of Epidemiology and BiostatisticsDepartment of Endocrinology and MetabolismInstitute of Sports MedicineDepartment of Parenteral and Enteral NutritionDepartment of Endocrinology and MetabolismDepartment of Endocrinology and MetabolismDepartment of Endocrinology and MetabolismMelbourne EpiCentreAims. Prediabetes has been proved as an important risk factor of both diabetes and cardiovascular disease (CVD). Previous studies have shown that both lifestyle intervention and pioglitazone may delay the development of diabetes in patients with prediabetes. However, no study has ever explored whether these interventions could revert prediabetes to normal glycemic status as the primary outcome. Interventions that may revert prediabetes back to normal glucose status would be of great clinical importance. Materials and Methods. We conducted a randomized, multicenter, 2×2 factorial designed study to examine whether intensive lifestyle intervention and/or pioglitazone could revert prediabetes to normal glucose tolerance. The participants were followed up for three years unless they reverted to normal glucose state or developed diabetes at the annual oral glucose tolerance test (OGTT). Reversion to normal glucose tolerance was confirmed on the basis of the results of OGTT. Results. In our study, 1945 eligible patients were ultimately randomized into four groups. In this three-year follow-up study, overall, 60.0%, 50.3%, 56.6% and 65.1% reverted back to normoglycemic state over 3 years of follow-up in the conventional lifestyle intervention plus placebo, intensive lifestyle intervention plus placebo, conventional lifestyle intervention plus pioglitazone, and intensive lifestyle intervention plus pioglitazone groups, respectively. Compared to the conventional lifestyle intervention plus placebo group, all the other three groups did not show any significant benefit in terms of reverting back to normoglycemic state. Conclusion. In our study, for patients with prediabetes, neither intensive lifestyle intervention nor pioglitazone had led to a higher reversion rate to normal glucose state. Trail registration.http://www.chictr.org.cn: ChiCTR-PRC-06000005.http://dx.doi.org/10.1155/2022/2971382 |
| spellingShingle | Yingying Luo Hongyuan Wang Xianghai Zhou Cuiqing Chang Wei Chen Xiaohui Guo Jinkui Yang Linong Ji Sanjoy K. Paul A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes Journal of Diabetes Research |
| title | A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes |
| title_full | A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes |
| title_fullStr | A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes |
| title_full_unstemmed | A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes |
| title_short | A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes |
| title_sort | randomized controlled clinical trial of lifestyle intervention and pioglitazone for normalization of glucose status in chinese with prediabetes |
| url | http://dx.doi.org/10.1155/2022/2971382 |
| work_keys_str_mv | AT yingyingluo arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT hongyuanwang arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT xianghaizhou arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT cuiqingchang arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT weichen arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT xiaohuiguo arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT jinkuiyang arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT linongji arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT sanjoykpaul arandomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT yingyingluo randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT hongyuanwang randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT xianghaizhou randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT cuiqingchang randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT weichen randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT xiaohuiguo randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT jinkuiyang randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT linongji randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes AT sanjoykpaul randomizedcontrolledclinicaltrialoflifestyleinterventionandpioglitazonefornormalizationofglucosestatusinchinesewithprediabetes |